Children, ADHD, PS, and DHA

In a randomized, double‑blind, placebo‑controlled trial, a small cohort of 36 children aged 4–14 years with ADHD (none previously medicated) received 200 mg/day of soy‑derived phosphatidylserine (PS) for two months.

Compared to placebo (n = 17), the PS group (n = 19) showed significant improvements in overall ADHD symptoms, inattention, hyperactivity‑impulsivity, short‑term auditory memory, and performance on a Go/No‑Go task (p < 0.05 or p < 0.01)   .

A later, larger trial involving 200 children evaluated a supplement combining PS (300 mg/day) with omega‑3 fatty acids (including a DHA dose of approximately 100 mg/day along with EPA), over 15 weeks, followed by an open‑label extension. This study found reduced impulsivity/restlessness and better emotional impact scores, sustained over 30 weeks  .

While this combination improved outcomes more than PS alone, the specific mention of 300 mg DHA daily enhancing PS efficacy is not directly documented in the peer‑reviewed literature I could locate. If that dosage figure appears in commentary or review articles, it likely stems from extrapolation rather than a randomized trial.

 **Only studied in children and adolescents**** — no published trials to date have assessed phosphatidylserine ± DHA supplementation in adults with ADHD